Manu Joshi

Competitive Intelligence Analyst

The Network Company • Freiberufler

Mar 2018 - Present • 8 yrs 2 mos

Deliver enterprise quality oncology competitive intelligence for pharmaceutical strategy, biotech, and investor clients. Work spans full CI landscape development, pipeline analysis, biomarker stratification, payer dynamics, regulatory intelligence, and strategic implications. Compteted 100+ CI reports with recent engagements of indications that include: 1. 1L Esophageal Squamous Cell Carcinoma (ESCC) US-focused CI landscape: 53 slides covering FDA-approved assets, ADC pipeline deep dives, biomarker battleground, US payer and formulary dynamics, and strategic catalyst watchlist 2. 1L c-KIT Mutant Melanoma CI landscape: molecular pathology, TKI pipeline, IO competitive threats, conference data synthesis across ASCO/ESMO/SMR 2024-2025 3. Neoadjuvant Rectal Cancer CI landscape: Phase 3 pipeline, TNT strategies, biomarker-driven treatment evolution 4. Use AI-augmented research workflows combining primary literature, FDA regulatory databases, ClinicalTrials.gov, and conference intelligence to deliver in days what traditionally takes weeks. Every deliverable is citation-verified against primary sources. 5. Delivered strategic intelligence that directly informed client decision-making including investment risk flags, competitive threat assessments, and catalyst watchlists identifying upcoming Phase 3 readouts, FDA decisions, and pricing inflection points that could materially impact commercial positioning and portfolio strategy